At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 8 enrolled
Drug / intervention
AZD9291drug
Likely dose
AZD9291 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Single-centre, Non-Randomised, Open-label, Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD9291 in Healthy Male Volunteers
In Brief
A Phase 1 clinical trial evaluating AZD9291 for Healthy Volunteers. Completed, enrolled 8 participants across 1 site.
Detailed Summary
Study to evaluate the pharmacokinetic and Mass Balance of single dose \[14C\] AZD9291 in healthy male volunteers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 2014
Enrollment StartMay 2014
Primary CompletionAug 2014
TodayJul 2026
First PostedMar 26, 2014
Enrollment StartMay 1, 2014
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 12.3 years ago
Interventions
AZD9291drug
Volunteer will receive a single oral dose of 20 mg \[14C\]-AZD9291 as a solution on Day 1